Opendata, web and dolomites

MCNANO SIGNED

“Multi-component nanoparticles as bimodal contrast agents for MRI and optical detection of tumors and for targeted photodynamic therapy”

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MCNANO project word cloud

Explore the words cloud of the MCNANO project. It provides you a very rough idea of what is the project "MCNANO" about.

shell    bimodal    cure    decorated    modular    nh2    cells    express    oh    degree    doped    drug    exhibit    lanthanide    tumor    chemistry    detection    earth    upconverted    diagnosis    nanoparticles    ultimately    attaching    light    upconverting    tissues    synthesize    combines    biocompatible    cancer    soluble    area    photoluminescence    tm3    tb3    infrared    er3    treatment    anti    combination    cyclic    bio    functionalization    nanoparticle    emitted    imaging    nano    blue    n3    will    disruptive    ions    visible    active    rare    spectroscopy    of    t2    contrast    time    excitation    strategies    core    offers    nanomatrix    region    excited    nanoprobes    cholesterol    multidisciplinary    fluoride    pt    synthesis    efficacy    simultaneous    agent    rgd    components    containing    efficient    py    first    therapeutic    folic    anchoring    platform    emission    photo    phototheranostic    suitable    clinical    yield    agents    receptors    optical    acid    moieties    dy3    covered    surface    simultaneously    ho3    mri    980    photoactivated    water   

Project "MCNANO" data sheet

The following table provides information about the project.

Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN 

Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000
website: www.kuleuven.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://onlinelibrary.wiley.com/doi/abs/10.1002/chem.201801815
 Total cost 172˙800 €
 EC max contribution 172˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 172˙800.00

Map

 Project objective

The main aim of this proposal is to synthesize a range of lanthanide containing nanoparticles with an upconverting core, that can be excited in the infrared region to yield emission in the visible range, as for MRI and optical imaging. The nanoparticles will be covered with a rare earth doped MRI active shell and decorated with targeting moieties, which offers a means of targeting cancer cells that greatly over express the receptors. Further we will develop “phototheranostic” agents by anchoring the photo active anti cancer drug in between the receptors and the surface of upconverting/MRI active nanoparticle. A platform for synthesis of water soluble, modular target specific bimodal agents based on nanoprobes will be developed that will exhibit efficient upconverted photoluminescence from the rare-earth ions (Er3/Tm3) doped into fluoride nanomatrix. Simultaneously, the Tb3/Dy3/Ho3 present at the shell will make them suitable as T2 contrast agents for MRI. Specific tumor targeting strategies will be developed by attaching targeting components like folic acid, cholesterol or cyclic-RGD to the surface of the nanoparticles. Functionalization of nanoparticles with [Pt(N3)2(OH)2(NH2-R)(py)] drug, which can be photoactivated by the blue light emitted from the nanoparticle core upon excitation at 980, will result in a novel phototheranostic anti-cancer agent. This system may allow a large degree of control of the therapeutic efficacy and ultimately lead to simultaneous diagnosis and treatment in clinical applications. The unique multidisciplinary approach adopted here which combines areas of nano-chemistry, spectroscopy and bio-imaging, is expected to lead to a disruptive change in the area of cancer research. The combination of these areas would allow for the first time the development of biocompatible “phototheranostic” agents for the simultaneous detection by MRI/optical imaging and cure of the cancer- affected tissues.

 Publications

year authors and title journal last update
List of publications.
2018 Silvanose Biju, Juan Gallo, M. Bañobre-López, Bella B. Manshian, Stefaan J. Soenen, Uwe Himmelreich, Luce Vander Elst, Tatjana N. Parac-Vogt
A Magnetic Chameleon: Biocompatible Lanthanide Fluoride Nanoparticles with Magnetic Field Dependent Tunable Contrast Properties as a Versatile Contrast Agent for Low to Ultrahigh Field MRI and Optical Imaging in Biological Window
published pages: , ISSN: 0947-6539, DOI: 10.1002/chem.201801814
Chemistry - A European Journal 2019-06-13
2018 Silvanose Biju, Tatjana Parac-Vogt
Recent Advances in Lanthanide Based Nano-architectures as Probes for Ultra High-Field Magnetic Resonance Imaging
published pages: , ISSN: 0929-8673, DOI: 10.2174/0929867325666180201110244
Current Medicinal Chemistry 25 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MCNANO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MCNANO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVENTS (2020)

Affective work-related daily events, and changing characteristics of the work context: New challenges for management practices to deliver employees’ well-being and workplace performance

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More  

RegARcis (2020)

Role of the SWI/SNF complex in the Androgen Receptor cistrome regulation

Read More